Artwork

Content provided by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

LuPSMA moves UpFront | first RCT data with Arun Azad and Michael Hofman

34:38
 
Distribuie
 

Manage episode 440040001 series 3350113
Content provided by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

A big day at ESMO in Barcelona today as our friend and colleague A/Professor Arun Azad presents the results of the UpFront PSMA trial for the first time. The data were revealed in the main prostate cancer session at ESMO and simultaneously published in Lancet Oncology. UpFront PSMA is a randomised controlled trial comparing ADT and docetaxel, with ADT + done + LuPSMA in men newly diagnosed high-volume mHSPC. This is a world-first readout of LuPSMA in a prospective randomised trial for mHSPC, and clearly shows a benefit. We dive into the details today with Arun, and another friend and colleague, Professor Michael Hofman, nuc med lead for UpFront PSMA.
This is a Themed Podcast supported by our Silver Partners, Novartis.
Even better on our YouTube channel
Full paper in Lancet Oncology here

  continue reading

151 episoade

Artwork
iconDistribuie
 
Manage episode 440040001 series 3350113
Content provided by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Professor Declan Murphy & Dr Renu Eapen, Professor Declan Murphy, and Dr Renu Eapen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

A big day at ESMO in Barcelona today as our friend and colleague A/Professor Arun Azad presents the results of the UpFront PSMA trial for the first time. The data were revealed in the main prostate cancer session at ESMO and simultaneously published in Lancet Oncology. UpFront PSMA is a randomised controlled trial comparing ADT and docetaxel, with ADT + done + LuPSMA in men newly diagnosed high-volume mHSPC. This is a world-first readout of LuPSMA in a prospective randomised trial for mHSPC, and clearly shows a benefit. We dive into the details today with Arun, and another friend and colleague, Professor Michael Hofman, nuc med lead for UpFront PSMA.
This is a Themed Podcast supported by our Silver Partners, Novartis.
Even better on our YouTube channel
Full paper in Lancet Oncology here

  continue reading

151 episoade

Toate episoadele

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință